Physician profile
Byron A Long
NPI 1225030182
$1,572.85
in general payments reported to CMS, 2019-2025
13 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $52.80 · 2021: $350 · 2022: $416 · 2023: $219 · 2024: $121 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $486.47 | 2021-2023 | Tepezza |
| Abbvie INC. | $352.89 | 2022-2025 | |
| Allergan, INC. | $310.20 | 2019-2022 | |
| New World Medical,INC. | $105.47 | 2023 | |
| Merz North America, INC. | $91.08 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $55.89 | 2019 | |
| Ocular Therapeutix, INC. | $44.79 | 2019 | |
| Merz Pharmaceuticals, LLC | $29.20 | 2022 | |
| Eyevance Pharmaceuticals LLC | $22.90 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.68 | 2019 | |
| Biotissue Holdings INC. | $19.06 | 2022 | |
| Galderma Laboratories, L.P. | $18.45 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.